In this regard, Nguyen and co-Workers have successfully visualized and quantified the effects of the anticancer drug Trastuzumab in a TME reconstituted on chip, composed by cancer-associated fibroblasts (CAF), an HER2+ breast cancer cell line (bearing a HER2-receptor gene amplification), and immune cells (Nguyen et al., 2018). This evidence concerns the gene ERBB2 and breast carcinoma.